The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $430.86

Today's change-2.12 -0.49%
Updated October 23 11:44 AM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $430.86

Today's change-2.12 -0.49%
Updated October 23 11:44 AM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc crosses below 200-day moving average

Regeneron Pharmaceuticals Inc is lower today, dropping (U.S.)$2.12 or 0.49% to (U.S.)$430.86 and crossing below its 200-day moving average. Shares have lost 3.33% over the last five days, but have gained 17.37% over the last year to date. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $435.00
  • Previous close(U.S.) $432.98
  • High(U.S.) $437.90
  • Low(U.S.) $430.05
  • Bid / Ask(U.S.) $430.50 / (U.S.) $430.92
  • YTD % change+17.37%
  • Volume312,396
  • Average volume (10-day)709,012
  • Average volume (1-month)806,707
  • Average volume (3-month)825,625
  • 52-week range(U.S.) $325.35 to (U.S.) $543.55
  • Beta1.57
  • Trailing P/E43.25×
  • P/E 1 year forward28.98×
  • Forward PEG1.61×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $9.96
Updated October 23 11:44 AM EDT. Delayed by at least 15 minutes.
S&P TSX0.13%Sector:HealthcareIndustry:Biotechnology

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue1,4701,3191,2271,220
Total other revenue--------
Total revenue1,4701,3191,2271,220
Gross profit857727673633
Total cost of revenue613592554587
Total operating expense920888880857
Selling / general / administrative307297326270
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income550431347363
Interest income (expense), net non-operating-5-8----
Gain (loss) on sale of assets--------
Other--------
Income before tax526432342366
Income after tax388249253265
Income tax, total13818388101
Net income388249253265
Total adjustments to net income--------
Net income before extra. items388249253265
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items388249253265
Inc. avail. to common incl. extra. items388249253265
Diluted net income388249253265
Dilution adjustment0--00
Diluted weighted average shares116115116116
Diluted EPS excluding extraordinary itemsvalue per share3.342.162.192.27
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share3.342.162.192.27